Akari Therapeutics PLC (AKTX) - Net Assets
Based on the latest financial reports, Akari Therapeutics PLC (AKTX) has net assets worth $28.33 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($47.89 Million) and total liabilities ($19.56 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check AKTX tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $28.33 Million |
| % of Total Assets | 59.15% |
| Annual Growth Rate | N/A |
| 5-Year Change | 409.99% |
| 10-Year Change | -16.93% |
| Growth Volatility | 274.17 |
Akari Therapeutics PLC - Net Assets Trend (2010–2025)
This chart illustrates how Akari Therapeutics PLC's net assets have evolved over time, based on quarterly financial data. See AKTX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Akari Therapeutics PLC (2010–2025)
The table below shows the annual net assets of Akari Therapeutics PLC from 2010 to 2025. For live valuation and market cap data, see AKTX company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $28.33 Million | +27.44% |
| 2024-12-31 | $22.23 Million | +9806.99% |
| 2023-12-31 | $-229.00K | -112.79% |
| 2022-12-31 | $1.79 Million | -67.76% |
| 2021-12-31 | $5.55 Million | -40.81% |
| 2020-12-31 | $9.38 Million | +144.64% |
| 2019-12-31 | $3.84 Million | -71.32% |
| 2018-12-31 | $13.38 Million | -33.05% |
| 2017-12-31 | $19.98 Million | -41.42% |
| 2016-12-31 | $34.10 Million | -30.00% |
| 2015-12-31 | $48.72 Million | +903.91% |
| 2014-12-31 | $4.85 Million | -16.53% |
| 2013-12-31 | $5.81 Million | +273.04% |
| 2012-12-31 | $-3.36 Million | -35.21% |
| 2011-12-31 | $-2.48 Million | -22.49% |
| 2010-12-31 | $-2.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Akari Therapeutics PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25391863700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $-782.00K | -2.76% |
| Other Components | $293.66 Million | 1036.64% |
| Total Equity | $28.33 Million | 100.00% |
Akari Therapeutics PLC Competitors by Market Cap
The table below lists competitors of Akari Therapeutics PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pure Biologics Spólka Akcyjna
WAR:PUR
|
$7.16 Million |
|
Yoshiharu Global Co.
NASDAQ:YOSH
|
$7.16 Million |
|
Locafy Ltd
NASDAQ:LCFY
|
$7.16 Million |
|
Syncona Limited
LSE:SYNC
|
$7.18 Million |
|
Chewathai Public Company Limited
BK:CHEWA
|
$7.15 Million |
|
Noble Financials SA
WAR:IBS
|
$7.15 Million |
|
Plant Advanced Technologies SA
PA:ALPAT
|
$7.15 Million |
|
Carbine Resources Ltd
AU:CRB
|
$7.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Akari Therapeutics PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 22,229,000 to 28,328,000, a change of 6,099,000 (27.4%).
- Net loss of 17,298,000 reduced equity.
- New share issuances of 10,725,000 increased equity.
- Other comprehensive income decreased equity by 44,000.
- Other factors increased equity by 12,716,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-17.30 Million | -61.06% |
| Share Issuances | $10.72 Million | +37.86% |
| Other Comprehensive Income | $-44.00K | -0.16% |
| Other Changes | $12.72 Million | +44.89% |
| Total Change | $- | 27.44% |
Book Value vs Market Value Analysis
This analysis compares Akari Therapeutics PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.36x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | $-607.03 | $12.00 | x |
| 2011-12-31 | $-743.57 | $12.00 | x |
| 2012-12-31 | $-1079.00 | $12.00 | x |
| 2013-12-31 | $1103.64 | $12.00 | x |
| 2014-12-31 | $975.87 | $12.00 | x |
| 2015-12-31 | $4574.17 | $12.00 | x |
| 2016-12-31 | $2316.59 | $12.00 | x |
| 2017-12-31 | $1.60 | $12.00 | x |
| 2018-12-31 | $676.99 | $12.00 | x |
| 2019-12-31 | $167.61 | $12.00 | x |
| 2020-12-31 | $237.66 | $12.00 | x |
| 2021-12-31 | $103.53 | $12.00 | x |
| 2022-12-31 | $22.95 | $12.00 | x |
| 2023-12-31 | $-1.87 | $12.00 | x |
| 2024-12-31 | $74.44 | $12.00 | x |
| 2025-12-31 | $33.66 | $12.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Akari Therapeutics PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -61.06%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.69x
- Recent ROE (-61.06%) is above the historical average (-173.26%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-472.13K |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.87 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.10 Million |
| 2013 | -62.26% | 0.00% | 0.00x | 1.35x | $-4.20 Million |
| 2014 | -198.80% | 0.00% | 0.00x | 1.34x | $-10.13 Million |
| 2015 | -93.02% | 0.00% | 0.00x | 1.43x | $-50.19 Million |
| 2016 | -53.20% | 0.00% | 0.00x | 1.35x | $-21.55 Million |
| 2017 | -139.77% | 0.00% | 0.00x | 1.45x | $-29.92 Million |
| 2018 | -149.15% | 0.00% | 0.00x | 1.23x | $-21.29 Million |
| 2019 | -439.16% | 0.00% | 0.00x | 2.69x | $-17.23 Million |
| 2020 | -182.02% | 0.00% | 0.00x | 1.56x | $-18.02 Million |
| 2021 | -313.69% | 0.00% | 0.00x | 2.10x | $-17.98 Million |
| 2022 | -990.95% | 0.00% | 0.00x | 7.72x | $-17.93 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.99 Million |
| 2024 | -89.03% | 0.00% | 0.00x | 2.27x | $-22.01 Million |
| 2025 | -61.06% | 0.00% | 0.00x | 1.69x | $-20.13 Million |
Industry Comparison
This section compares Akari Therapeutics PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Akari Therapeutics PLC (AKTX) | $28.33 Million | 0.00% | 0.69x | $7.15 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Akari Therapeutics PLC
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat s… Read more